Company's Solutions

Founded in 2004, BMT Diagnostics is an Israeli company focusing on bringing innovative products and developing customer-friendly rapid diagnostic tests.

Having identified the need for more user-friendly and accurate rapid diagnostic tests, BMT has developed and pioneered a first of its kind Lab-On-Time™ worldwide patented platform of No-Step IVDR integrated diagnostic devices that include Strep A, COVID19 Ag, and Influenza A+B tests that greatly simplifies rapid diagnostic testing.

Other test that we supply are Infectious disease, Fertility Early markers of disease Urinalysis and urinary tract infection (UTI) Drugs of abuse, blood markers and more Using this platform, we have reduced test performance complexity to a single step, making it simpler and more intuitive.

This platform improves the process of patient screening shifting patient screening from centralized labs to point-of-care, improving HMO service.

We continuously strive to improve our products offering, paying close attention to our existing long term customers needs and feedback. We take pride in participating in the ongoing point-of-care diagnostics revolution, making rapid tests more accurate and simpler to use and supporting the transition of diagnostic tests from central labs to the physician’s office and from there to patients’ homes.

BMT is constantly in the process of expanding its product line, both by improving its existing products and adding novel ones to its portfolio.

We are seeking both – importers and distributors in major territories for our current products.

Prominent Case Study

Evaluation Study for the usability of BMT’s Influenza A+B Lab-On-Time™ Test Device :

The test was validated at the Tzafon Medical Center, Poriya, Israel in Feb-Mar 2023 under the supervision of Prof. Avi Peretz.

This evaluation study compared the diagnostic test results obtained using BMT Diagnostics Lab-On-Time Influenza A+B Rapid Test Device with the diagnostic test results obtained with a PCR test performed in the lab on 170 nasal samples obtained from healthy (100) and influenza patients. From this study, it is concluded that the specificity of BMT’s rapid test is 100%, whereas the overall sensitivity was found to be 75.7%.

Further analysis performed according to PCR CT values obtained for nasal samples from influenza patients demonstrated that when considering only CT cutoff values of <35 the overall sensitivity of BMT’s rapid test increased to 84.1%.

Furthermore, full correlation was observed between influenza types (A or B) determined by the PCR test and the results obtained with BMT’s rapid test.

Finally, BMT’s rapid test device has been shown to be very user friendly. Test performance is very intuitive and involves only a single step of sample collection and placement of the test device in the provided, pre-filled reagent tube. Test results were clear and obtained in less than 10 min following nasal sample collection by the device.

It is my professional opinion that BMT Diagnostics Lab-On-Time Influenza A+B Rapid Test Device could be used by the general population as a self-test due to its simplicity, ease of use, and clear results reading.